青肠化湿颗粒联合5-氨基水杨酸治疗中度活动性溃疡性结肠炎:多中心随机双盲安慰剂对照试验方案
本研究为多中心、随机、双盲、安慰剂对照优效性试验,计划纳入120例中度活动性溃疡性结肠炎患者,随机接受青肠化湿颗粒或安慰剂12周,两组均给予美沙拉秦4 g/日基础治疗。主要结局为临床缓解率,次要结局包括健康相关生活质量、内镜应答率、黏膜愈合率及炎症标志物。研究旨在评估青肠化湿颗粒联合美沙拉秦诱导缓解的优效性。
要点
- 青肠化湿颗粒联合美沙拉秦4 g/日与安慰剂联合美沙拉秦比较,主要终点为临床缓解率。
- 计划纳入120例中度活动性UC患者,来自中国10家医院,干预12周,随访24周。
- 次要结局包括生活质量、内镜应答率、黏膜愈合率及粪便钙卫蛋白和CRP等炎症标志物。
核心结论
- 该试验旨在验证青肠化湿颗粒联合美沙拉秦在诱导中度活动性UC缓解方面是否优于安慰剂联合美沙拉秦。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照优效性试验,计划从中国10家医院招募120例中度活动性UC患者。
- eligible患者随机接受青肠化湿颗粒或安慰剂治疗12周,两组均接受美沙拉秦4 g/日基础治疗。
- 整个研究周期36周,包括24周随访,按意向性治疗原则在第2、4、6、8、10、12周评估变量。
关键数值与推荐
- 主要结局为临床应答(缓解)率。
- 次要结局包括健康相关生活质量、内镜应答率、黏膜愈合率及炎症标志物(如粪便钙卫蛋白和CRP)。
临床怎么用
- 若试验显示青肠化湿颗粒显著优于安慰剂,可为临床医生、UC患者和政策制定者提供更明智的决策依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ulcerative colitis (UC) is an intestinal inflammatory disease characterized by inflammation of the colonic mucosa. With unknown pathogenesis, it has become a chronic lifetime disorder worldwide. In patients with moderately active UC, several therapies (e.g., aminosalicylates, corticosteroids, immunosuppressants, and biologics) are recommended for induction (or maintenance) of remission. Given the side effects and disease burden, it is difficult for most patients to achieve ideal treatment goals in clinical practice. Chinese herbal medicine (CHM), as a complementary therapy, has been widely used in the management of UC in China. Qing-Chang-Hua-Shi granule (QCHS) is a classical Chinese herbal formula. Our preliminary study suggested that the QCHS decoction has a significant effect on patients with moderately active UC. However, its effectiveness and safety has not been evaluated convincingly. Therefore, we designed this protocol to investigate the efficacy of QCHS granule for moderately active UC. METHODS: This is a multicenter, randomized, double-blind, placebo-controlled, superiority trial. A total of 120 patients with moderately active UC will be recruited from 10 hospitals in China. Each eligible participant will be randomly assigned to receive QCHS granule or placebo for 12 weeks. Both groups will be given basic treatment with mesalazine (4 g/day). The primary outcomes are the clinical response (remission) rate. The secondary outcomes are health-related quality of life, endoscopic response rate, mucosal healing rate, and inflammatory markers (e.g., fecal calprotectin and CRP). The whole study period will last 36 weeks, including 24 weeks follow-up time. According to the intention-to-treat principle, variables will be assessed at 2, 4, 6, 8, 10, and 12 weeks after study commencement. DISCUSSION: This is the first randomized controlled clinical study protocol regarding Chinese herbal extract granules in the management of moderately active UC. We aim to investigate the superiority of QCHS granules over placebo in terms of induction of remission. If the trial shows significant benefits of QCHS granules, it will help clinical practitioners, UC patients, and policymakers make more informed choices in the decision-making. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-IOR-14005554 . Registered on 27 November 2014.
引用
- Shen Z, Zheng K, Zou J, et al. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials. 2021. PMID: 33441157. doi:10.1186/s13063-020-05012-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。